Gust Deborah A, Soud Fatma, Hardnett Felicia P, Malotte Charles K, Rose Charles, Kebaabetswe Poloko, Makgekgenene Lebogang, Henderson Faith, Paxton Lynn, Segolodi Tebogo, Kilmarx Peter H
*Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA; †Center for Healthcare Innovation, California State University, Long Beach, CA; ‡Currently, Department of Health Sciences, California State University, Long Beach, CA; §Department of Public Health Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana; ∥Division of Global HIV/AIDS and TB, CDC-Botswana, Gaborone, Botswana; and ¶Currently, Fogarty International Center, National Institutes of Health, Bethesda, MD.
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):556-563. doi: 10.1097/QAI.0000000000001143.
Among participants of a clinical trial to test the efficacy of tenofovir/emtricitabine in protecting heterosexual men and women living in Botswana from HIV infection, the aim was to determine (1) if sexual risk behavior, specifically condomless sex acts and number of sex partners, changed over time, (2) factors associated with condomless sex acts and number of sex partners, and (3) the effect of participant treatment arm perception on risk behavior to address the possibility of risk compensation.
A longitudinal modeling of rates of risk behaviors was used to determine if the rate of condomless sex acts (#acts/person) and rate of sex partners (#partners/person) changed over time and which factors were associated with behavior change.
One thousand two hundred participants were analyzed over 1 year. There was a 25% decrease in the rate of sex partners among participants sexually active in the last 30 days. The rate of reported condomless sex acts was greater for males [rate ratio (RR) = 1.34; confidence interval (CI): 1.07 to 1.67] and participants whose sexual debut in years was ≤15 years of age (RR = 1.65; CI: 1.14 to 2.38) and 16-17 (RR = 1.68; CI: 1.22 to 2.31) compared with those ≥20 years. Rate of reported sex partners was greater for males (RR = 3.67; CI: 2.86 to 4.71) and participants whose age at sexual debut in years was ≤15 (RR = 2.92; CI: 2.01 to 4.22) and 16-17 (RR = 2.34; CI: 1.69 to 3.24) compared with those ≥20. There was no effect of participant treatment arm perception on risk behavior.
Our study of preexposure prophylaxis to prevent HIV infection found no evidence of risk compensation which may have been due to participants' motivations to reduce their risk behaviors and risk-reduction counseling.
在一项测试替诺福韦/恩曲他滨预防博茨瓦纳异性恋男女感染艾滋病毒疗效的临床试验参与者中,目的是确定:(1)性风险行为,特别是无保护性行为和性伴侣数量是否随时间变化;(2)与无保护性行为和性伴侣数量相关的因素;(3)参与者对治疗组的认知对风险行为的影响,以解决风险补偿的可能性。
采用风险行为发生率的纵向模型来确定无保护性行为发生率(行为数/人)和性伴侣发生率(伴侣数/人)是否随时间变化,以及哪些因素与行为变化相关。
对1200名参与者进行了为期1年的分析。在过去30天内有性行为的参与者中性伴侣发生率下降了25%。与20岁及以上者相比,男性无保护性行为发生率更高[率比(RR)=1.34;置信区间(CI):1.07至1.67],首次性行为年龄≤15岁的参与者(RR = 1.65;CI:1.14至2.38)以及16 - 17岁的参与者(RR = 1.68;CI:1.22至2.31)。报告的性伴侣发生率男性更高(RR = 3.67;CI:2.86至4.71),首次性行为年龄≤15岁的参与者(RR = 2.92;CI:2.01至4.22)以及16 - 17岁的参与者(RR = 2.34;CI:1.69至3.24)高于20岁及以上者。参与者对治疗组的认知对风险行为没有影响。
我们关于暴露前预防以预防艾滋病毒感染的研究未发现风险补偿的证据,这可能是由于参与者有降低风险行为的动机以及风险降低咨询。